诺卡菌眼内炎的诊断、临床表现与结局
这项多中心回顾性介入病例系列纳入25眼培养证实的诺卡菌眼内炎,主要病因为白内障术后(75%)。体外药敏对万古霉素差、对阿米卡星最佳,确诊或高度怀疑时首选玻璃体腔注射阿米卡星。
要点
- 诺卡菌眼内炎多发生于白内障术后(18/25眼,75%)
- 体外药敏万古霉素差、阿米卡星最佳,确诊或高度怀疑时首选玻璃体腔阿米卡星
核心结论
- 诺卡菌眼内炎初诊视力差时视觉结局非常不乐观。
- 诊断确认或高度怀疑时,首选玻璃体腔注射阿米卡星。
研究设计与样本
- 多中心回顾性介入病例系列,纳入25例(25眼)培养证实的诺卡菌眼内炎患者。
- 所有病例均送检前房液和/或玻璃体和/或人工晶状体做微生物学评估。
- 排除非诺卡菌病因及培养阴性者,收集人口学、临床表现、干预及最终视觉与解剖结局。
主要发现
- 平均年龄54.7±22.9岁;18眼(75%)为白内障术后(在外院手术),3眼(12.5%)为外伤后,3眼(12.5%)为内源性。
- 末次随访平均14.25±30.35个月,中位数2个月。
- 体外药敏对万古霉素差,对阿米卡星最佳。
关键数值与推荐
- 体外药敏:万古霉素差,阿米卡星最佳。
临床怎么用
- 对疑似诺卡菌眼内炎应尽早行微生物学检查以确诊。
- 诊断确认或高度怀疑诺卡菌时,首选玻璃体腔注射阿米卡星。
- 初诊视力差者预后需谨慎告知。
局限性
- 回顾性、多中心病例系列,样本量25眼较小。
- 末次随访时间变异大(平均14.25±30.35个月,中位数2个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe the clinical presentations, diagnosis, and management outcomes of Nocardia endophthalmitis. DESIGN: Retrospective, interventional, multicenter case series. METHODS: The study was conducted in a multicentric institutional practice setup and included 25 eyes of 25 patients with culture-proven Nocardia endophthalmitis. Anterior chamber fluid and/or vitreous and/or intraocular lens were submitted for microbiological evaluation in all cases. Patients with non-Nocardia etiology and those that were culture negative were excluded. Case records were studied and data regarding demography, clinical presentations, interventions received, and final visual and anatomic outcomes were noted. The main outcome measures were final visual outcomes and factors determining them. RESULTS: The mean age of the patients was 54.7 ± 22.9 years. By the etiology of infection, 18 (75%) eyes were post-cataract surgery (operated elsewhere), 3 (12.5%) eyes were posttrauma, and 3 (12.5%) eyes were endogenous. The final follow-up was a mean of 14.25 ± 30.35 months, median 2 months. The odds of a favorable outcome were 42.5 (95% confidence interval [CI] 3.15 to 571.84, P = .0047) when the vision was more than hand motions at presentation, 9.42 (95% CI 0.92 to 95.89, P = .05) in male sex, 21 (95% CI 0.9 to 489.7, P = .05) when presentation was within 48 hours, and 2.5 (95% CI 0.23 to 26.48, P = .44) with primary vitrectomy instead of a biopsy. The in vitro susceptibility was poor for vancomycin and was best for amikacin. CONCLUSIONS: The visual outcome in Nocardia endophthalmitis is very guarded when presenting vision is poor. On diagnostic confirmation or high index of suspicion, intravitreal amikacin is preferred.
引用
- Dave VP, Pathengay A, Sharma S, et al. Diagnosis, Clinical Presentations, and Outcomes of Nocardia Endophthalmitis. Am J Ophthalmol. 2018. PMID: 30240723. doi:10.1016/j.ajo.2018.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。